Variation in cervical and breast cancer screening coverage in England: a cross-sectional analysis to characterise districts with
![Amazon.com: Environmental Chemistry: A global perspective (9780199228867): vanLoon, Gary W., Duffy, Stephen J.: Books Amazon.com: Environmental Chemistry: A global perspective (9780199228867): vanLoon, Gary W., Duffy, Stephen J.: Books](https://images-na.ssl-images-amazon.com/images/I/41QDxh0rmPL._SX366_BO1,204,203,200_.jpg)
Amazon.com: Environmental Chemistry: A global perspective (9780199228867): vanLoon, Gary W., Duffy, Stephen J.: Books
Explaining the better prognosis of screening-exposed breast cancers: influence of tumour characteristics and treatment
![Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial - The Lancet Oncology Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/f3f0fe69-221c-4e18-958d-23bbdde09733/gr2.jpg)
Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial - The Lancet Oncology
![Stephen DUFFY | Professor (Full) | Cleveland State University, OH | Department of Civil and Environmental Engineering Stephen DUFFY | Professor (Full) | Cleveland State University, OH | Department of Civil and Environmental Engineering](https://i1.rgstatic.net/ii/profile.image/278759258247174-1443472794727_Q512/Stephen-Duffy-7.jpg)
Stephen DUFFY | Professor (Full) | Cleveland State University, OH | Department of Civil and Environmental Engineering
![Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial - The Lancet Oncology Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/360e98b4-f833-4ae3-bb8c-0fe5eda89339/gr1.gif)